Roskamp Institute Inc
2040 Whitfield Avenue
Sarasota FL 34243

The mission of the Roskamp Institute, Inc. is to conduct scientific research to discover safe and effective new therapies to successfully treat diseases of the mind and to promote healthy aging.

CEO/Executive Director Dr. Fiona Crawford Ph.D.
Board Chair Mr. Robert Roskamp
Board Chair Affiliation CEO, Roskamp Management Company, LLC
General Info
Tax Exempt Status Public Supported Charity
Incorporation Year 2011
State Charitable Solicitations Permit Yes Aug 2018
State Registration Yes May 2018
Financial Summary
Note: Revenue includes the value of in-kind contributions/donations
IRS Letter of Determination
IRS Letter of DeterminationView
Impact Statement

The Roskamp Institute was established with the goal of becoming a primary international center for leading-edge research on brain disorders, particularly Alzheimer’s Disease. Today, the Institute is recognized as a global leader in the effort to understand and ultimately cure debilitating diseases of the mind.

In addition to its cutting-edge medical and pharmaceutical research on the molecular level of the brain, the Institute operates a neurology and memory clinic that translates laboratory discoveries into patient treatments.  The Clinic’s signature offering is a free, confidential memory screen for anyone age 60 or older.  This is when the first signs of mild cognitive impairment are usually identified and when it is still possible to alter the course of Alzheimer’s Disease through lifestyle, diet and medicine.


The Roskamp Institute is one of the most unique public charitable entities in the Sarasota Manatee area. It is a research center, a healthcare provider and an educational facility training tomorrow’s research scientists. The Institute has the only accredited PhD program in the area, via the world-wide Open University, UK. The best international molecular biology students work side by side with seasoned scientists to learn while participating in the highest level of peer-reviewed research. The Institute also welcomes the best students from colleges and universities throughout the world to apply for and participate in structured internship programs in molecular biology, chemistry, genetics, proteomics and mass spectrometry.


Recognizing that enthusiasm and accomplishment in science often occurs early in a developing student, the Roskamp Institute has reached out to area high school science and technology programs to offer mentoring and assistance. The Institute has a partnership advising an area High School Technology Students Association which has resulted in selected high school students volunteering as interns in chemistry and genetics.

Needs Statement

1.  Endowed Research Chairs: $2,500,000 each Roskamp Institute scientists depend on grant funds from government and private agencies.  Endowed Chairs provide consistent resources, allowing the Institute to attract and retain the best scientists.

2.   Facilities Analysis: $400,000 RI needs a complete facilities analysis of its 28 year old building and resources to bring about the much needed changes in electrical, data storage, HVAC to meet the Institute’s needs.

3.   PhD student’s 3 year tuition: $150,000 RI has the only PhD molecular science program in the Sarasota area. It is crucial that qualified scientists are trained in the field and then retained in permanent positions. There is room for additional students if tuitions and stipend scholarships, $50,000 per year, were available.

4.   Permanent Equipment: $2,000 - $750,000 The Institute uses extremely specialized equipment in its research. The development office has a complete list. Prime needs range between a bench-top centrifuge for $2,000 and a triple quad mass spectrometer at $750,000.

Background Statement

The Roskamp Institute, the world renowned research laboratory located in Sarasota, has made important discoveries with profound clinical implications for the millions of Americans with neurological disorders. 


The Roskamp Institute established its research facilities and team of scientists in Sarasota in 2003. (At that time the Sarasota-based Roskamp Foundation provided the administrative and organizational structure for the innovative Institute.) Now, after only eight years the Institute has become firmly established as a leading body in the international research community with its programs and projects supported by the National Institutes of Health, the U.S. Department of Defense, the Veterans Administration, the European Commission Seventh Framework Programme and several other national and international peer-reviewed agencies.

In 2010, the Foundation’s governing board determined that the growth of the Roskamp Institute could be accommodated by a change in status from a private operating foundation to a public charity with full tax-deductible status under the IRS not-for-profit (501[c]3) designation. This autonomy – which occurred in January 2011 – allows the Institute to continue to build its research programs and secure a broader range of grants and charitable gifts to support the development of new drugs and therapies to treat neurological disorders such as Alzheimer's Disease, head trauma, Gulf War Illness, Autism, drug addiction and Tourette's Syndrome.

The groundwork for the Institute’s research programs took place more than two decades ago when Roskamp’s two lead researchers – Dr. Michael Mullan, the Institute’s President and CEO and Dr. Fiona Crawford, its Associate Director – were part of a pioneering team of British scientists at London University. This group discovered that the onset of Alzheimer’s Disease was directly related to the accumulation in the brain of a protein called beta-amyloid. This work led to the Roskamp Institute’s development of novel treatments for Alzheimer's Disease which are now in clinical trials.

Areas Served
Areas Served
FL- Sarasota
FL- Manatee
FL- Charlotte
Areas Served Comments

The Roskamp Institute has a unique, international/local geographic scope. We have clinical trials in Europe and throughout the US, research exchange study programs in China and Japan and students and guest scientists from Africa, the Mid East, India and the United Kingdom. Our Clinic serves the direct needs of people in Sarasota, Manatee and the surrounding counties, plus visitors who come here, especially in the winter, for their annual memory screens and evaluations.

Service Categories
Primary Org Type Medical Research
Secondary Org Type Diseases Disorders & Medical Disciplines
Tertiary Org Type Science & Technology
Statement from the Board Chair/Board President

In 2010, the Foundation’s governing board determined that the growth of the Roskamp Institute could be best accommodated by a change in status from a private operating foundation to a public charity with full tax deductible status under the IRS not-for-profit (501[c]3) designation


With this change in structure, the Roskamp Foundation’s two principals – Bob and Diane Roskamp – have made an important gift to the world health community, providing substantial resources to aid the discovery of new drugs and treatments for debilitating diseases. As part of this gift, all the Foundation’s assets previously supporting the Institute – including intellectual and real property – were given to this new, independent, public charity - the Roskamp Institute, Inc.


 “Through the years, Diane and I have been privileged to participate in many wonderful opportunities to make the world a better place. Our passion lies most directly with using our time and resources to find a cure for diseases of the mind. We believe that through the continued and expanded work of the Roskamp Institute, Alzheimer's Disease and many other debilitating disease will be understood and cured. By making the Roskamp Institute a public charity, Diane and I believe that cures will happen in our lifetime ” - Bob Roskamp

Statement from the CEO/Executive Director

With strong support from private philanthropists, our quest to solve the mysteries of Alzheimer’s disease and other neurological disorders is making excellent progress.  Our Institute’s leading-edge studies are supported by peer-reviewed funding from the National Institutes of Health, the U.S. Department of Defense, the Veterans Administration and other national and international agencies.

One of our most important findings was showing that accumulation of beta-amyloid promotes the development of Alzheimer's Disease. This finding led to the search for new ways of treating the disease and resulted in Roskamp Institute researchers identifying medicines that can potentially prevent the disease. One of these drugs is in phase III clinical trials in Europe and represents a huge accomplishment for the Institute - very few drugs have ever entered such late stage trials for Alzheimer's Disease.

Our current research objectives include discovering new and effective treatments for other brain disorders particularly those that involve inflammation of the brain. We are testing drugs and naturally occurring compounds that have anti-inflammatory properties to combat a wide range of age-related degenerative disorders. For instance, we have initiated clinical studies of a natural compound in tobacco that Institute research has shown to inhibit inflammation and the accumulation of amyloid in the brain, and we are collaborating with researchers at Johns Hopkins School of Medicine for other medical applications of this compound.

Our scientific team is also conducting studies in areas that complement our extensive Alzheimer's Disease research, such as new our military research program which includes the search for treatments for Traumatic Brain Injury, Post Traumatic Stress Disorder and Gulf War Illness. For these studies we collaborate with the Veterans Administration and military bases around the country. 

We also have an active childhood disorders research program that explores the role of inflammation in autism and related disorders.

The Roskamp Institute is exceptional in that it is completely dedicated to the discovery of new cures for brain disorders and has no competing aims allowing total focus on true ‘translational” discoveries that have very quickly moved from the laboratory to the clinic. Our successes encourage us and our supporters to apply our proven approach to increase the number of new medicines and nutraceuticals we deliver to relieve the burden of suffering caused by these sometimes devastating disorders.

President and CEO, Fiona Crawford 

In addition, to the research and clinical components of The Roskamp Institute, a Ph.D. program has been establish jointly with Open University and offers a doctoral degree in Neuroscience. To date, three people have earned their Ph.D.’s and have remained at The Roskamp Institute to continued their post doctorate education and research.


The Institute’s primary goal is to discover new and effective drug treatments for diseases of the brain; in particular, Alzheimer's disease. Lead researchers have shown that certain genetic variations may predispose humans to Alzheimer's disease; giving scientists clues about the Alzheimer's disease process. This led to the identification of a small protein called ß(beta)-amyloid as central to the disease process. Much of the research conducted by the Institute involves experimentation on ways to prevent ß-amyloid from accumulating and damaging the brain.

The Roskamp research team discovered that Nilvadipine, an anti-hypertension drug approved for use in Europe, can stop the accumulation of ß-amyloid proteins in the brain. Phase III clinical trials of Nilvadapine is ongoing in 13 European countries in a placebo-controlled study involving 500 patients with Alzheimer’s disease.  As of June, 2015 met its enrolment goal and the study should concluded in 18 months with results to follow.

Budget $3,030,500
Category Medical Research, General/Other Alzheimer Disease Research
Program Linked to Organizational Strategy Yes
Population Served Aging, Elderly, Senior Citizens Adults General/Unspecified
Short Term Success

Short-term success will be measured by the outcomes of clinical trials of drugs and nutraceuticals that are about to begin in Europe and the United States. These trials will test compounds developed by the Roskamp Institute that we believe effectively reduce brain inflammation. Clinical trials on humans are underway at this time in the US on a nutritional supplement that has been shown in experimental models to reduce the formulation of inflammation and ß(beta)-amyloid. Results of these trials will be analyzed in 2012 and findings will be published in scientific journals.


The Roskamp Institute has a significant success rate in its scientific research and has published important peer-reviewed papers on its findings.

Long Term Success

The ultimate long-term success for this program will be to achieve a cure for Alzheimer’s disease and to find ways to prevent the occurrence of the disease. Finding a vaccine for polio is perhaps the best model for the success of this program, although eventually a polio vaccine was discovered that protects people from contracting the disease. The goal that the Institute strives for is to find a cure for Alzheimer’s disease that is also effective in curing or reversing other neurological disorders that are caused by the accumulation of ß-amyloid proteins and inflammation in the brain.

Program Success Monitoring

Findings of Roskamp Institute scientific research programs are ultimately presented in scientific papers, reports and posters which are reviewed by peer scientists in specific research areas. Roskamp scientists present their findings at national and international seminars and symposiums where they are subject to the scrutiny and critique of the world’s top research scientists.  Institute research that is funded by such sources as the National Institutes of Health, the National Science Foundation, Alzheimer’s Association, the U.S. Department of Defense, the Veterans Administration, the European Commission Seventh Framework Programme have gone through rigorous review by professional scientists.

Program Success Examples

NILVAD, an international research consortium led by Trinity College Dublin (Ireland,) will, in 2012, begin a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial to study the effectiveness of Nilvadipine. NILVAD, a $8.4 million program, is funded by the European Commission Seventh Framework Programme.


Brian Lawlor of Trinity College, who leads NILVAD, said “only a handful of Alzheimer’s drugs have ever reached this stage, and most were developed by major pharmaceutical companies. It’s a tremendous achievement for a research institute like Roskamp. The process can move more quickly in Europe, and the findings may help accelerate the acceptance process with the U.S. Food and Drug Administration.” The clinical trials will take be taking place in Europe where Nilvadipine is already approved for use in mild cases of hypertension. 


In studies that complement the extensive Alzheimer's research of the Roskamp Institute, other aspects of neuronal dysfunction, degeneration and repair are being examined through work on traumatic brain injury (TBI). With over 1 million TBI cases in the US each year, TBI is a common and major health problem. An estimated 5.3 million Americans are living today with a TBI-related disability.


New studies led by Fiona Crawford, Ph.D., associate director of the Institute, could lead to better diagnosis and eventual treatment for US military personnel and other patients with TBI. We have found that there are changes in blood proteins after a head injury, and they are dependent on the severity of the injury, the time since the injury and genetic factors influencing outcomes after head injury. Crawford’s work is supported by the U.S. Dept of Defense and the Veterans Administration, as it may lead to better diagnosis of soldiers with brain injuries and better long-term care of veterans.

Budget $826,500
Category Medical Research, General/Other Head Injury Research
Program Linked to Organizational Strategy Yes
Population Served People/Families with of People with Disabilities Adults People/Families with of People with Psychological Disabilities
Short Term Success

The Roskamp Institute has recently taken voluntary blood samples from Alabama National Guard troops prior to their deployment to battle zones in Afghanistan. Following their return – in the fall of 2012 – they will be given a full psychological workup which will include debriefings of the battle field experiences they had including any injuries they may have suffered. These will be some of the first human findings that Institute scientists will review and will be compared to the molecular findings from previous experimental models. If a positive comparison is found it could lead to new techniques in diagnosis, treatment and management of disorders that follow TBI, including post-traumatic stress disorder, depression and migraine headaches.

Long Term Success

Ultimately the Institute hopes to develop protocols that will record blood protein levels of individuals prior to their exposure to circumstances that could lead to traumatic brain injury (TBI.) While currently the most pressing concern is injuries sustained by US troops in battle, other occupations and even leisure-time and sports activities can lead to TBI. If blood level proteins are recorded as a base-line for a healthy individual, these levels can then be compared following head injuries, concussions and other trauma to indicate a level of change. Early determination of a change in blood protein characteristics should allow health care professionals to provide early and more effective treatments. Oftentimes patients do not recognize the severity of traumatic head injuries when they occur and unnecessarily postpone diagnosis and treatment.

Program Success Monitoring

The program will exam returning soldiers and study their blood protein samples. Dr. Crawford presented her laboratory findings at the North American Brain Injury Society and the National Neurotrauma Symposium. A peer-reviewed paper on Dr. Crawford’s potentially prognostic and diagnostic biomarkers for TBI has just been published in the Journal of Neurotrauma, while a second study relating to potential therapeutic approaches has been submitted for publication.

Program Success Examples

Recent experimental model studies of the effects of TBI on blood protein levels and led to support by the Department of Defense for continued, more detail research. This includes the aforementioned National Guard studies and work with other military units. This research program has also received the support of the James B. Haley Veterans Administration Hospital in Tampa.


The Roskamp Institute Clinic specializes in the diagnosis of Alzheimer’s disease and related disorders, mild cognitive impairment and cognitive dysfunction secondary to brain damage or disease. The Clinic hosts a fully functioning neurology clinic providing diagnostic and clinical services to dementia patients and their caregivers and offers free, confidential baseline memory screenings to people over 60.


The clinical team consists of experienced specialists in geriatrics, neuropsychology and neuroradiology. Led by the Institute’s director, Dr. Mike Mullan, and the Clinic’s director, Dr. Andrew Keegan, the Clinic has expertise in assessing the earliest cognitive symptoms and stages of Alzheimer’s disease and related dementias.


In addition, the Clinic performs phase II - IV clinical research studies in the specific areas of  Alzheimer's disease, dementia, mild cognitive impairment, depression, traumatic brain injury, multiple sclerosis, Parkinson’s disease and Tourette's syndrome.

Budget $1,212,200
Category Health Care, General/Other Early Intervention & Prevention
Program Linked to Organizational Strategy Yes
Population Served Aging, Elderly, Senior Citizens People/Families of People with Health Conditions Adults
Short Term Success

In the past year Dr. Andrew Keegan has brought his private practice into the Clinic and the number of patients being seen has nearly doubled. We have seen the number of memory screens increase from 1 to 2 a week in 2010 to an average of 5 to 7 a week in the past six months. Clinical trials of new neurology drugs have increased slightly over the past year.

Long Term Success

The Clinic is approaching capacity in terms of the number of neurology patients that it can see and treat effectively. Our long-term goal is an expansion of staff, facilities and hours and perhaps the opening of satellite offices.  We are striving to get everyone over the age of 60 to come in for an annual memory screen to first establish a baseline and then track any changes that may occur. Early identification of for Alzheimer’s disease has shown to lead to more effective management. Also memory screens can help diagnose other types of dementia that may not be Alzheimer’s disease – such as vascular or depression-based – but may be treatable with medication and other therapies.

Program Success Monitoring

As Alzheimer’s disease is a cognitive disorder with no cure, success is monitored primarily by how many patients we are seeing for memory screens and for early diagnosis.

Program Success Examples

Recently the Roskamp Institute Clinic heard from a man who was in Sarasota to visit his uncle.   When he arrived his uncle did not recognize him, his house was in disarray and there was no food in the refrigerator. He did not know anyone in town who could help, but his uncle’s next door neighbor was familiar with the Roskamp Institute and had received a free memory screen. The nephew called the Institute Clinic and his uncle was seen the next afternoon for a memory screen and neurological workup.  


A week later the uncle had been diagnosed by the Clinic’s neurologist as having early symptoms of Alzheimer’s and also a vascular problem that was keeping blood and oxygen from reaching his brain. Both of these conditions were treatable and he is receiving regular care from the staff at the Clinic, who also provided him with resources and contacts to get home care assistance as well as regular visits to the Clinic.


The Roskamp Institute is also committed to educating and training tomorrow's scientists.  In 2009, the Roskamp Institute was granted a license from the Florida Dept of Education, Commission for Independent Education to begin a PhD program in biomolecular biology.  Doctoral students can now work with Institute scientists, performing hands-on, laboratory-based research to gain practical knowledge and expertise so that they will complete their studies as a fully qualified professional. The Institute enrolls from three to five students in its PhD program per year.  These students are currently studying and working on research into Gulf War syndrome, traumatic brain injury and Alzheimer’s disease. 

 Recognizing the need to encourage even younger students to pursue the sciences, the Roskamp Institute has created a nationally recognized outreach program for local high school students. The Institute scientists  actively volunteer their time and expertise to guide and coach these young minds. Members of Manatee County’s Southeast High School Technology Student Association Team were crowned national champions in 2009 and reached the national finals  in 2010 with their attempt solve the problem of harvesting spider silk via goat’s milk to create a silk as strong as the fabric used in the body armor Kevlar. The Institute hopes to expand this program to all area high schools and local colleges.

Budget $31,550
Category Medical Research, General/Other Medical Disciplines & Occupations Research
Program Linked to Organizational Strategy Yes
Population Served US& International General/Unspecified Adolescents Only (13-19 years)
Short Term Success

Three students have just been added to the program for the 2012-2015 academic period. The program could handle two additional students but current budget limitations have capped the number at three. (Students are given a stipend for living expense.) To fill these three spots, 50 qualified students applied. From the first class receiving their PhDs, one graduate is working for the FDA, one teaches at the University of Miami and one teaches at Broward College. Current PhD students have published in excess of 50 peer-reviewed scientific papers on the research areas of Gulf War Illness and Alzheimer’s disease.

Long Term Success

If successful to the extent we hope, this PhD program could be a major player in re-stocking the field of American-trained scientists. There is a dearth of scientists in the world who have been trained in the United States and then have taken positions in important US research facilities. This is especially critical in southwest Florida where the Roskamp Institute / Open University program is the only PhD granting institution. Trends in medical and scientific education show that students tend to take up permanent residence in geographic areas where they do their internships and final coursework.

Program Success Monitoring

Each PhD student works closely with an Institute scientist on grant supported research. Students’ progress is quickly measured by the quality of the work that the supervising scientist sees. Students either publish their own papers or are listed as co-authors with the faculty/scientist they are working with.


The objectives of the high school TSA program are to bring talented high school science students into state of the art research laboratories to work directly with internationally recognized medical research scientists, to stimulate interest among area high school students in pursuing careers in science, medicine, research and technology and to provide superior education to the highest achieving students in the area.

Program Success Examples

The PhD program is a highly competitive program with a 6% acceptance rate: three from 50 applicants for 2012. Recent PhD recipients hold positions with major institutions and current students are publishing their work independently and alongside Institute scientists.

South East High School (Manatee) students participating in the Technology Student Association program at the Institute were awarded first place in the 2011 State of Florida BioTech Design division competition and then took their project to the national competition in Dallas, Texas where they earned third place. After the competition, three members of the team worked at Roskamp as summer volunteer interns. In addition, an honors student from Pine View School in Osprey, works as an intern in the Institute’s chemistry department.

CEO/Executive Director
CEO/Executive Director Dr. Fiona Crawford Ph.D.
CEO Term Start Jan 2011
CEO/Executive Director Email

Dr. Fiona Crawford leads all operational aspects of The Roskamp Institute and Clinic.  Her Ph.D. research contributed to the identification of two mutations in the β-amyloid precursor protein (ßAPP) gene which cause early onset Alzheimer’s disease, discoveries which led to two publications in Nature (Goate et. al., 1991; Chartier-Harlin et. al., 1991). Her discovery of a third Alzheimer’s causing mutation, the so-called “Swedish” mutation, together with her colleague Dr. Michael Mullan (Mullan et. al., Nature Genetics, 1992), led to the development of the first valid mouse models of Alzheimer’s Disease. Following completion of her Ph.D. research in 1992 she moved to the University of South Florida, where she was the Associate Director of the Roskamp Laboratories, which subsequently was established as the Roskamp Institute for research into psychiatric disorders. By 2003, she held an endowed chair at USF and was Associate Professor in three departments. However, the Roskamp Institute relocated that year to a stand-alone facility in Sarasota and Dr. Crawford accepted the position of Associate Director, becoming the President in 2013. Though her appointment with the James A. Haley Veterans’ Hospital she has pursued collaborative research projects including studies of Alcoholism, Traumatic Brain Injury (TBI) and Post Traumatic Stress Disorder (PTSD). She has led the development of a novel mouse model of mild TBI (Mouzon et al., J Neurotrauma, 2012; Mouzon et. al., Annals of Neurology, 2013), and uses such good laboratory models of human conditions to identify novel therapeutic approaches. She is utilizing state-of-the-art proteomic and lipidomic technology to identify peripheral biomarkers and molecular targets in TBI and other complex conditions of relevance to the military, such as PTSD and Gulf War Illness, and she is the Director of Militarily Relevant Research and Program Director of the Ph.D. program at the Roskamp Institute. She is funded by the VA, NIH and DoD.

Former CEOs/Executive Directors
Dr. Michael Mullan Jan 2003 - July 2013
Senior Staff
Dr. Andrew Keegan MDAssociate Director, Roskamp Institute Clinic
Nichole Russ Director of Finance and Administration
Staff & Volunteer Statistics
Full Time Staff 51
Part Time Staff 4
Staff Retention Rate % 92
Professional Development Yes
Contractors 1
Volunteers 7
Management Reports to Board Yes
CEO/Executive Director Formal Evaluation Yes
Senior Management Formal Evaluation Yes
Non-Management Formal Evaluation Yes

Albert Einstein College of Medicine, Yeshiva University

Algerian American Foundation for Culture, Education, Science, and Technology
Alzheimer’s Association

Boston University

Cambridge University, UK

Centre de Développement des Technologies Avancées, Algeria

Columbia University

Cornell University

Duke University

Emory University

Fudan University Shanghai Medical College

Harvard Medical School

James A. Haley Veterans Hospital, Tampa

James J. Peters VA Medical Center, The Bronx

Johns Hopkins University

Karolinska Institute, Stockholm

Max Planck Institute, Frankfurt

Massachusetts General Hospital

Massachusetts Institute of Technology

McGill University

Mote Marine Lab

Mount Sinai Medical College

New College

Northwestern University

Open University, UK

Peking University Medical School, Beijing

South East High School, Manatee

State College of Florida

Sunshine from Darkness, Sarasota

Pineview School, Sarasota

Trinity College Dublin

UC-Los Angeles

UC-San Diego

UC-San Francisco

University of Chicago

University of Florida

University of Glasgow

University of Gothenburg

University of Helsinki

University of Miami

University of Munich

University of South Florida, Sarasota-Manatee

University of South Florida, Tampa

University of Tokyo

University of Washington

External Assessments and Accreditations
Awards & Recognition
Golden Appreciation Award WinnerArea Agency on Aging for Southwest Florida2011
finalist, “Be more knowledgeable.” Educational OutreachWEDU Be More… awards2012
Champion of Healthcare - Innovation/ResearchManatee Chamber of Commerce2013
BioFlorida Chapter AwardBioFlorida2014
Risk Management Provisions
Accident and Injury Coverage
Boiler and Machinery
Commercial General Insurance
Commercial General Liability
Commercial General Liability and D and O and Umbrella or Excess and Automobile and Professional
Commercial General Liability and Medical Malpractice
Computer Equipment and Software
Crime Coverage
Directors and Officers Policy
Disability Insurance
General Property Coverage and Professional Liability
Life Insurance
Medical Health Insurance
Medical Malpractice
Patient Liability
Workers Compensation and Employers' Liability
Government Licenses
Organization Licensed by the Government Yes
Fundraising Plan No
Communication Plan No
Strategic Plan No
Strategic Plan Years
Strategic Plan Adopted 0
Management Succession Plan Yes
Continuity of Operations Plan No
Nondiscrimination Policy Yes
Whistle Blower Policy Yes
Document Destruction Policy No
Directors and Officers Insurance Policy No
Policies and Procedures Yes
Multi-Media Comments by Organization
Board Chair
Board Chair Mr. Robert Roskamp
Company Affiliation CEO, Roskamp Management Company, LLC
Board Term Feb 2010 to Dec 2017
Board Chair Email
Board Members
Board Members
Mr. Tom Aarts Community Volunteer
Dr. Fiona Crawford PhDPresident & CEO, The Roskamp Institute, Inc.
Dr. Michael Hoffmann MDJames A. Haley Veteran's Hospital
Dr. Michael Mullan Ph.D.Community Volunteer
Dr. Patricia Isbell Ordorica MDPhysician, Private Practice
Mr. Robert Roskamp CEO, Roskamp Management Company, LLC
Mr. Scott Sensenbrenner CEO, Enzymedica
Mrs. Carol Waters Department of Elder Affairs
Constituency Includes Client Representation Yes
Board Ethnicity
African American/Black 0
Asian American/Pacific Islander 0
Caucasian 8
Hispanic/Latino 0
Native American/American Indian 0
Other 0 0
Board Gender
Male 5
Female 3
Unspecified 0
Board Term Lengths 2
Board Term Limits 99
Board Orientation Yes
Number of Full Board Meetings Annually 2
Board Meeting Attendance % 94
Board Self-Evaluation Yes
Written Board Selection Criteria Yes
Board Conflict of Interest Policy Yes
% of Board Making Monetary Contributions 100
% of Board Making In-Kind Contributions 100
Standing Committees
Development / Fund Development / Fund Raising / Grant Writing / Major Gifts
Scientific Advisory
Board Governance
Governance Comments by Organization

The Roskamp Institute is a scientific research not for profit, public supported charity. The Institute was formed at USF in Tampa in 1998, bringing to the US the very best scientists in the world who were working to find cures for devastating diseases of the brain, especially Alzheimer’s. The Institute incorporated in late 2009, began gathering and completing the legal and formal documents of a not for profit in 2010 and received its official 501 c 3 IRS classification in January 2011.

One year later we are moving off the starting line of a most exciting venture and the board is united in seeing to it that the Institute fulfills its mission “to successfully treat diseases of the mind” in our lifetime. The board has set the following goals and invites everyone with energy, willingness, skills and resources to join us in accomplishing them:

 - Energize the local and national Alzheimer’s and mental health communities to the challenges and opportunities of our work

 - Bring together a board with a broad sphere of knowledge and influence to spread the word and help gather the resources to make our work even more successful

 - Reach out to other educational institutions locally, state-wide, across the country and around the world to form partnerships and collaborations so knowledge and discoveries can be shared and new research can be taught to bright new scientists

 - Form a leadership Scientific Advisory Council to advise the Institute on directions in research, drug discovery, treatment and education

History shows us that the roads that led to the curing some of the most devastating diseases were long, fraught with pitfalls, expensive and frustrating. The Roskamp Institute is dedicated to the long-run; to finding the cures for Alzheimer’s and other terrifying diseases that keep so many people from leading the full, rewarding long lives they deserve.

Current Year Projections
Tax Year Start Month Jan
Tax Year Start Day 01
Tax Year Begins 2017
Tax Year End Month Dec
Tax Year End Day 31
Tax Year Ends 2017
Projected Revenue $6,049,000.00
Projected Expenses $5,542,099.00
Total Projected Revenue includes "in-kind" contributions/ donations No
Organization has Endowment No
Capital Campaign
Currently In a Capital Campaign No
Campaign Purpose
Campaign Goal
Amount Raised To Date 0 as of 0
IRS Form 990s
Audit/Financial Documents
Financial Review
Revenue SourcesHelpThe financial analysis involves a comparison of the IRS Form 990 and the audit report (when available) and revenue sources may not sum to total based on reconciliation differences. Revenue from foundations and corporations may include individual contributions when not itemized separately.
Fiscal Year201620152014
Foundation and
Corporation Contributions
Government Contributions$2,205,347$1,942,618$2,199,365
Individual Contributions$1,769,145$1,441,361$1,591,486
Investment Income, Net of Losses$38,658$15,674$11,072
Membership Dues$0$0$0
Special Events$0$0$0
Revenue In-Kind$0$0$0
Expense Allocation
Fiscal Year201620152014
Program Expense$4,257,574$4,565,959$4,865,372
Administration Expense$1,787,902$2,008,369$1,982,904
Fundraising Expense$3$203$30
Payments to Affiliates$0$0$0
Total Revenue/Total Expenses0.910.950.94
Program Expense/Total Expenses70%69%71%
Fundraising Expense/Contributed Revenue0%0%0%
Assets and Liabilities
Fiscal Year201620152014
Total Assets$6,095,593$7,090,859$7,301,351
Current Assets$656,511$1,565,281$1,318,357
Long-Term Liabilities$256,301$444,931$458,088
Current Liabilities$291,424$526,428$368,587
Total Net Assets$5,547,868$971,359$6,474,676
Top Funding Sources
Fiscal Year201620152014
Top Funding Source & Dollar AmountGovernment Grants - Unspecified $2,205,347Clinical Research $2,818,193Clinical Research $2,697,217
Second Highest Funding Source & Dollar AmountContributions, gifts, grants $1,769,145Government Grants - Unspecified $1,942,618Government Grants - Unspecified $2,199,365
Third Highest Funding Source & Dollar AmountClinical Research $1,399,053Contributions, gifts, grants $1,441,361Contributions, gifts, grants $1,591,486
CEO/Executive Director Compensation $125,001 - $150,000
Tax Credits No
Short Term Solvency
Fiscal Year201620152014
Current Ratio: Current Assets/Current Liabilities2.252.973.58
Long Term Solvency
Fiscal Year201620152014
Long-Term Liabilities/Total Assets4%6%6%
Financials Comments
Financial Comments by Organization

Financial Comments by Foundation
Financial information taken from Federal 990.  Contributions include foundation and corporate support.
Nonprofit Roskamp Institute Inc
Address 2040 Whitfield Avenue
Sarasota, FL 34243
Phone 941 752-2949